Connecticut Attorney General William Tong has escalated enforcement against the sale of bootleg GLP-1 weight loss drugs, sending cease and desist letters to clinics in Avon, Brookfield, and Danbury. These businesses were marketing compounded semaglutide and tirzepatide injections falsely implying FDA approval, in violation of Connecticut’s Unfair Trade Practices Act and public health guidelines.

The businesses - CT Weight Loss Shot in Danbury, Vigorous 360 Wellness in Brookfield, and Radiance Medspa in Avon - allegedly prescribed non-FDA-approved GLP-1 drugs while being operated by individuals who are not licensed healthcare providers. Such clinics cannot legally offer medical treatment in Connecticut.

“There are currently no generic GLP-1 weight loss injections on the market, and anyone advertising or offering this is not telling the truth and exposing patients to potentially unsafe bootleg drugs. Our ongoing investigation into these knockoffs found three clinics, owned or controlled by laypeople, not licensed healthcare providers, deceptively marketing these compounded injections in Connecticut. We have sent cease-and-desist letters to each of these clinics, and will not hesitate to take further action to protect patients and consumers,” said Attorney General William Tong.

The crackdown follows a broader investigation into illegally marketed compounded drugs and a settlement with Triggered Brand, which sold unregulated GLP-1s online. Tong has also joined a bipartisan coalition urging the FDA to take stronger action against counterfeit drug distribution and to strengthen oversight of compounding pharmacies.

This latest enforcement reinforces Connecticut’s commitment to protecting consumer health from deceptive medical practices.